Last reviewed · How we verify
beclomethasone HFA
Beclomethasone is a corticosteroid that reduces inflammation in the airways by suppressing immune cell activity and inflammatory mediator release.
Beclomethasone is a corticosteroid that reduces inflammation in the airways by suppressing immune cell activity and inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | beclomethasone HFA |
|---|---|
| Also known as | QVAR |
| Sponsor | Milton S. Hershey Medical Center |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Beclomethasone binds to glucocorticoid receptors in airway tissues, leading to decreased production of inflammatory cytokines, reduced recruitment of eosinophils and other immune cells, and decreased mucus production. This anti-inflammatory action reduces airway obstruction and hyperresponsiveness in asthma and COPD.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Tremor
- Headache
- Dysphonia
- Throat irritation
Key clinical trials
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma (PHASE3)
- Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. (PHASE3)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (PHASE2)
- Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- beclomethasone HFA CI brief — competitive landscape report
- beclomethasone HFA updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI